Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The development of effective new treatments is greatly facilitated by the understanding of the mechanisms of disease. In rheumatoid arthritis, there has been progress in understanding its immunology, the HLA class II predisposition including the 'shared epitope' and more recently in understanding the importance of proinflammatory cytokines. Here we review our work in defining TNFalpha as a therapeutic target in rheumatoid arthritis, from an understanding of molecular pathogenesis in vitro, to formal proof in the clinic in vivo. There is now extensive clinical use of anti-TNFalpha biologicals for severe rheumatoid arthritis in the US and Europe.

Original publication

DOI

10.1016/s1169-8330(01)00259-9

Type

Journal article

Journal

Joint, bone, spine : revue du rhumatisme

Publication Date

01/2002

Volume

69

Pages

12 - 18

Addresses

Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, London, UK. m.feldmann@ic.ac.uk

Keywords

Humans, Arthritis, Rheumatoid, Tumor Necrosis Factor-alpha, Antirheumatic Agents, Antibodies, Monoclonal, Treatment Outcome, Drug Evaluation, Preclinical, Clinical Trials as Topic